Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_129e393582e6bdf4029baf2206522f45 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2013-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2016-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bff695bcb240f2403f6645eb83e98861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e4f800f86737e395cdf5599cafbaff1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cc0528072c4ddfb3545aae484fe76b2 |
publicationDate |
2016-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9266958-B2 |
titleOfInvention |
Pharmaceutical composition for treatment and/or prevention of cancer |
abstract |
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11137401-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11547761-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9982059-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11110178-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9796775-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016208014-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400164-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9862774-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10675358-B2 |
priorityDate |
2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |